Key statistics
As of last trade LAVA Therapeutics NV (4PKB:FRA) traded at 1.41, 7.63% above its 52-week low of 1.31, set on Dec 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.41 |
---|---|
High | 1.41 |
Low | 1.41 |
Bid | 1.40 |
Offer | 1.66 |
Previous close | 1.47 |
Average volume | 136.67 |
---|---|
Shares outstanding | 26.29m |
Free float | 18.73m |
P/E (TTM) | -- |
Market cap | 42.06m USD |
EPS (TTM) | -0.8976 USD |
Data delayed at least 15 minutes, as of Nov 26 2024 07:05 GMT.
More ▼
Announcements
- LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
- LAVA Announces Annual Meeting of Shareholders
- LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
- LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
- LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
- LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
- LAVA Announces Clinical Development Milestone Achieved by Pfizer for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
- LAVA Therapeutics Announces Collaboration with Merck & Co., Inc., Rahway, NJ, USA to Evaluate LAVA-1207 in Combination with KEYTRUDA®
More ▼